ERBB2 and cancer: Here, we confirmed a significant lower level of miR-652-3p not only in Luminal A cancer patients (estrogen receptor [ER]/progesterone receptor [PR] positive and human epidermal growth factor receptor 2 [HER2] negative), as previously reported [14]], but also in non-Luminal A cancer patients, versus controls (p = 0.020 for Luminal A and p = 0.004 for non-Luminal A) (Additional file 1: Figure S3).